Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Revenue:
Total Revenue	$ 20,704	$ 30,136	$ 51,826	$ 59,665
Operating expenses:
Research and development	4,169	3,330	8,576	6,765
Selling and marketing	10,701	13,943	28,285	26,420
General and administrative	7,957	6,920	15,770	13,824
Intangible asset amortization	1,273	266	2,548	533
Total operating expenses	31,755	33,236	75,077	64,832
Loss from operations	(11,051)	(3,100)	(23,251)	(5,167)
Interest expense	(65)	(235)	(120)	(538)
Other income, net	91	841	630	1,294
Net loss and comprehensive loss	$ (11,025)	$ (2,494)	$ (22,741)	$ (4,411)
Net loss per common share, basic and diluted (in dollars per share)	$ (0.22)	$ (0.05)	$ (0.45)	$ (0.10)
Shares used to compute net loss per common share, basic and diluted (in shares)	50,212,123	45,586,081	50,002,377	43,389,540
Testing [Member]
Revenue:
Total Revenue	$ 15,212	$ 26,686	$ 42,203	$ 52,075
Operating expenses:
Cost of revenue	6,471	8,777	17,039	17,290
Product [Member]
Revenue:
Total Revenue	1,713	0	5,122	0
Operating expenses:
Cost of revenue	932	0	2,491	0
Biopharmaceutical [Member]
Revenue:
Total Revenue	3,779	1,450	4,501	5,590
Operating expenses:
Cost of revenue	$ 252	$ 0	$ 368	$ 0